ADVFN US – Market Content Editor
-

Pfizer shares slip despite encouraging trial results for eczema treatment
Pfizer Inc (NYSE:PFE) shares declined 1.15% to $26.74 in premarket trading Monday, even after the pharmaceutical company reported positive mid-stage clinical trial results for its experimental antibody therapy targeting atopic dermatitis. The drugmaker said the antibody, tilrekimig, showed meaningful improvement in symptoms of the chronic inflammatory skin condition during the study. According to Pfizer, a…
-

Relmada Therapeutics shares jump 25% after promising bladder cancer trial results
Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) climbed 25% on Monday after the company released 12-month interim results from its Phase 2 study of NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The trial reported a 12-month complete response (CR) rate of 76%, while 95% of patients achieved a complete response at some point…
-

ZIM Integrated Shipping tops Q4 estimates as revenue comes in above forecasts
ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) reported fourth-quarter results on Monday that surpassed analyst expectations, posting adjusted earnings per share of $0.32 compared with the consensus estimate of a $0.99 loss. Revenue for the quarter totaled $1.48 billion, slightly above the analyst forecast of $1.45 billion. However, sales were down 32% from $2.17 billion recorded…
-

ACCO Brands shares drop more than 3% after weak outlook despite meeting earnings forecasts
ACCO Brands Corporation (NYSE:ACCO) released fourth-quarter results on Monday that met analyst earnings expectations but missed on revenue and included fiscal 2026 guidance that came in well below market forecasts. Shares of the company declined 3.58% in pre-market trading after the announcement, as investors focused on the weaker outlook despite the in-line quarterly earnings performance.…
-

Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the gene-editing company posting a smaller-than-expected loss and stronger revenue. The company reported a loss of $0.06 per share, beating the consensus estimate for a $0.23 loss. Revenue totaled $24.74 million, well above the analyst forecast of $8.02 million, although…
-

BETA Technologies shares slide as wider loss overshadows strong revenue growth
BETA Technologies, Inc. (NYSE:BETA) reported fourth-quarter revenue of $11.1 million on Monday, representing a 151% increase from $4.4 million in the same period a year earlier. However, the electric aerospace company posted a larger-than-expected loss, with adjusted earnings per share of -$2.02 for the quarter ended December 31, 2025. The company’s shares dropped 2.91% in…
-

Heritage Insurance shares climb more than 5% after strong Q4 earnings beat
Heritage Insurance Holdings, Inc. (NYSE:HRTG) reported fourth-quarter results on Monday that came in ahead of analyst expectations, supported by stronger underwriting results and significantly lower catastrophe-related losses. Following the announcement, the insurer’s shares gained 5.62% in pre-market trading. The property and casualty insurance company posted adjusted earnings per share of $2.15 for the quarter, far…
-

Aureus Greenway shares jump on planned drone merger backed by Trump family
Shares of Aureus Greenway Holdings (NASDAQ:AGH) surged 55% after The Wall Street Journal reported that the company plans to merge with drone manufacturer Powerus, which is supported by investments tied to President Trump’s sons. According to the report, Eric Trump and Donald Trump Jr. are backing Powerus through their investment firm American Ventures. The transaction…
-

Korn Ferry shares drop nearly 5% despite earnings beat as guidance tempers outlook
Korn Ferry (NYSE:KFY) reported third-quarter results on Monday that came in above Wall Street expectations but issued a cautious outlook for the upcoming quarter. Shares of the global consulting firm declined 4.73% in pre-market trading following the announcement, as investors reacted to the company’s guarded guidance. For the third quarter, Korn Ferry posted adjusted earnings…
-

Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platform
Novo Nordisk (NYSE:NVO) is planning to distribute its weight-loss medications through the telehealth platform operated by Hims & Hers Health (NYSE:HIMS), signaling an unexpected thaw in relations between the companies after a recent legal clash, Bloomberg reported over the weekend. Shares of Hims — which have fallen roughly 51% so far this year — jumped…